Volume 32, Number 10—October 2026
Research
Multisectoral Emergence of Multidrug-Resistant Campylobacter coli Sequence Type 10042 Lineage, Europe, 2018–2025
Table 3
Campylobacter coli ST10042 isolates phenotypic and genotypic (antimicrobial resistance profiles in study of multisectoral emergence of multidrug-resistant C. coli ST10042 lineage, Europe, 2018–2025*
| Class | Antibiotic | Phenotype, n = 98, NRL-GI Portugal isolates |
Genotype, N = 217, all isolates |
||||
|---|---|---|---|---|---|---|---|
| Disk, mm, or MIC, mg/L | Susceptibility | No. tested/ no. positive | Resistance determinants | No. tested/ no. positive | |||
| Fluoroquinolones |
Ciprofloxacin |
6 mm |
R |
98/98 |
GyrA Thr86Ile |
217/217 |
|
| Tetracyclines |
Tetracycline |
6 mm |
R |
98/98 |
tet(32/O/32) | 213/217 | |
| tet(O) |
4/217 |
||||||
| β-lactams | Ampicillin | >256 mg/L | R | 98/98 | blaOXA-61 | 216/217 | |
| blaOXA-61 promoter: −57G>T | |||||||
| Amoxicillin/clavulanic acid | >256 mg/L | R | 1/98 | blaOXA-61 | 1/217 | ||
| blaOXA-61 promoter: −57G>T | |||||||
| −69delA | |||||||
| porA 35 | |||||||
| 12–64 mg/L | R | 95/98 | blaOXA-61 | 211/217 | |||
| blaOXA-61 promoter: −57G>T | |||||||
| porA 35/1006/4736 | |||||||
| 8/0.094 mg/L | S | 2/98 | blaOXA-61 | 4/217 | |||
| blaOXA-61 promoter: −57G>T | |||||||
| – | blaOXA-61 | 1/217 | |||||
| porA 35 |
|||||||
| Carbapenems |
Ertapenem |
0.30–1.0 mg/L | DS | 96/98 | porA 35/1006/4736† | 213/217 | |
| 0.032/0.125 mg/L |
S |
2/98 |
x |
4/217 |
|||
| Macrolides | Erythromycin | 6 mm/>256 mg/L | R | 2/98 | 23S rRNA (A2075G) | 6/217 | |
| 23S rRNA (A2074G) | 1/217 | ||||||
| 23S rRNA (A2074C) | 1/217 | ||||||
| >24 mm | S | 96/98 | x | 209/217 | |||
*Dash indicates no antimicrobial susceptibility testing was performed. X indicates absence of resistance determinants. DS, decreased susceptibility; NRL-GI, National Reference Laboratory for Gastrointestinal Infections; R, resistant; S, susceptible; ST, sequence type. †porA 1006 and porA 4736 differ from allele 35 by a single synonymous substitution. Other genetic determinants included: aadE (n = 1/217), aad9 (n = 1/217), aph(3′)-IIIa (n = 1/217) and ant (6)-Ia (n = 3/217). Gentamicin was tested and found to be susceptible for NRL-GI Portuguese isolates (>17 mm). Zone diameter breakpoints for ciprofloxacin (S >26 mm), tetracycline (S >30), and erythromycin (S >24 mm), and MIC breakpoint for erythromycin (S <8 mg/L) established by EUCAST v16.1 were used; interpretive criteria for ampicillin (S <8 mg/L), amoxicillin/clavulanic acid (S <8 mg/L), and ertapenem (S <1 mg/L), established by the CA-SFM V.1.1 were used.
1These authors contributed equally to this work and share first authorship.